Syndax Q1 Revuforj rev $20M, Niktimvo rev $13.6M; sNDA for mNPM1 AML

Syndax Pharmaceuticals Inc

2025-Q1 EPS reported -$0.98 revenue$20,042,000

Revuforj net revenue $20.0M in first full quarter; Niktimvo net revenue $13.6M (Incyte reported) in first partial quarter.
Submitted sNDA seeking Priority Review for revumenib in R/R mNPM1 AML under FDA RTOR program.
Initiated EVOLVE-2 pivotal frontline trial of revumenib + venetoclax/azacitidine in mNPM1 and KMT2Ar AML.
Net loss $84.8M ($0.98 per share) vs $72.4M ($0.85 per share) year ago; cash $602.1M.
Full-year 2025 R&D guidance $260-280M, total R&D+SG&A $415-435M; expects to reach profitability.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.